Leukemia Clinical Trial
Official title:
A Phase 2 Trial of Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Who Are Ineligible for Other Leukemia Protocols
The goal of this clinical research study is to learn if the combination of azacitidine and vorinostat can help to control AML or MDS better than azacitidine alone. The safety of this drug combination will also be studied.
The Study Drugs:
Azacitidine is designed to block certain genes in cancer cells whose job is to stop the
function of the tumor-fighting genes. By blocking the "bad" genes, the tumor-fighting genes
may be able to work better.
Vorinostat is designed to cause chemical changes in different groups of proteins that are
attached to DNA (the genetic material of cells), which may slow the growth of cancer cells or
cause the cancer cells to die.
Study Groups:
If you are found to be eligible to take part in this study, you will be randomly assigned (as
in the flip of a coin) to 1 of 2 groups.
- If you are in Group 1, you will receive azacitidine and vorinostat.
- If you are in Group 2, you will receive azacitidine alone.
For the first 40 patients, you will have an equal chance of being in either group. After the
first 40 patients, you will have a higher chance of being assigned to a group based on the
results from previous participants.
Study Drug Administration:
On Days 1-5 of every cycle, you will receive azacitidine by vein over 15-30 minutes.
If you are in Group 1, you will also take vorinostat by mouth 3 times a day with food on Days
1-5 of every cycle.
If you cannot take vorinostat by mouth during a cycle, you will receive only azacitidine
during that cycle. You will begin taking vorinostat by mouth again when you are able.
Your dose of study drugs may be lowered if you experience side effects.
You may receive a drug such as ondansetron before each dose of azacitidine to prevent nausea
and vomiting.
If you have diarrhea, you will take a drug such as Imodium (loperamide) to prevent diarrhea.
Study Visits:
Once a week of Cycle 1, the following tests and procedures will be performed:
- Your complete medical history will be recorded.
- You will have a physical exam.
- You will be asked if you have experienced any intolerable side effects.
- Blood (about 1-2 tablespoons) will be drawn for routine tests.
On Day 28 of Cycle 1 (+/- 3 days), you will have bone marrow aspiration to check the status
of the disease. To collect a bone marrow aspirate, an area of the hip is numbed with
anesthetic, and a small amount of bone marrow is withdrawn through a large needle.
If the doctor thinks it is needed, you will have extra bone marrow aspirations during the
later cycles to check the status of the disease.
One (1) time each cycle of Cycles 2 and beyond, the following tests and procedures will be
performed:
- Your complete medical history will be recorded.
- You will have a physical exam.
- You will be asked if you have experienced any intolerable side effects.
- If the doctor thinks it is needed, blood (about 2 tablespoons) will be drawn for routine
tests.
Length of Study:
You will be on active study for up to 12 cycles (about 12-18 months). You will be taken off
study if the disease gets worse or you experience intolerable side effects.
This is an investigational study. Vorinostat is FDA approved and commercially available for
the treatment of cutaneous T-cell lymphoma. Azacitidine is FDA approved commercially
available for the treatment of MDS. The combination of these drugs for use in patients with
intermediate-1 or higher risk MDS and AML is investigational.
Up to 80 participants will take part in this study. All will be enrolled at MD Anderson.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
| Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
| Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
| Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
| Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
| Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
| Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
| Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
| Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
| Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
| Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
| Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
| Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
| Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
| Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
| Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A | |
| Completed |
NCT00858117 -
A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL
|
Phase 2 |